Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1000613

CC(C)Oc1ccc(NC(=O)c2cccc(S(=O)(=O)N3C[C@@H]4C[C@H]3CN4C)c2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ELOVL6 Q9H5J4 7/20 0.49
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD11B1 P28845 1/20 0.44
HTT P42858 1/20 0.43
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42
NPC1 O15118 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TRPV4 Q9HBA0 1/20 0.42
CPT2 P23786 1/20 0.41
CPT1A P50416 1/20 0.41
CPT1B Q92523 1/20 0.41
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1001405 0.82 ELOVL6 (0.56) ELOVL6MEN1KMT2AHTTLMNA
SCHEMBL1000783 0.81 ELOVL6 (0.49) ELOVL6MEN1KMT2AHTTLMNA
SCHEMBL1000753 0.81 ELOVL6 (0.49) ELOVL6MEN1KMT2AHTTLMNA
SCHEMBL1001242 0.81 ELOVL6 (0.61) ELOVL6MEN1KMT2AHTT
SCHEMBL999626 0.81 ELOVL6 (0.59) ELOVL6MEN1KMT2AHTTLMNA
Trifluoroacetic Acid SCHEMBL1000490 0.79 MEN1 (0.51) MEN1KMT2AHTTLMNAGAA
SCHEMBL1000615 0.79 HSD11B1 (0.45) ELOVL6HSD11B1
Trifluoroacetic Acid SCHEMBL1002014 0.79 KMT2A (0.53) MEN1KMT2AHTTLMNAGAA
SCHEMBL1001481 0.75 KMT2A (0.56) ELOVL6MEN1KMT2AHTTLMNA
SCHEMBL1001743 0.75 KMT2A (0.56) ELOVL6MEN1KMT2AHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP disclosed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US disclosed
EP-2280001-A1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT Banyu Pharmaceutical Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT ELOVL1, ELOVL6, ELOVL3 ELOVL6 2/4885MEN1 4600/4885KMT2A 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.